Targeted proteomics driven verification of biomarker candidates
associated with breast cancer aggressiveness

J 2017

Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness

PROCHÁZKOVÁ, Iva, Juraj LENČO, Alena FUČÍKOVÁ, Jiří DRESLER, Lenka ČÁPKOVÁ et. al.

Basic information

Original name

Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness

Authors

PROCHÁZKOVÁ, Iva (203 Czech Republic, belonging to the institution), Juraj LENČO (203 Czech Republic), Alena FUČÍKOVÁ (203 Czech Republic), Jiří DRESLER (203 Czech Republic), Lenka ČÁPKOVÁ (203 Czech Republic, belonging to the institution), Roman HRSTKA (203 Czech Republic), Rudolf NENUTIL (203 Czech Republic) and Pavel BOUCHAL (203 Czech Republic, belonging to the institution)

Edition

Biochimica et Biophysica Acta - Proteins and Proteomics, AMSTERDAM, Elsevier Science, 2017, 1570-9639

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10608 Biochemistry and molecular biology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.609

RIV identification code

RIV/00216224:14310/17:00095604

Organization unit

Faculty of Science

DOI

http://dx.doi.org/10.1016/j.bbapap.2017.02.012

UT WoS

000400714800004

Keywords in English

Breast cancer; Selected reaction monitoring; mTRAQ; Estrogen receptor; Tumor grade; Lymph node

Abstract

V originále

Breast cancer is the most common and molecularly relatively well characterized malignant disease in women, however, its progression to metastatic cancer remains lethal for 78% of patients 5 years after diagnosis. Novel markers could identify the high risk patients and their verification using quantitative methods is essential to overcome genetic, inter-tumor and intra-tumor variability and translate novel findings into cancer diagnosis and treatment. We recently identified 13 proteins associated with estrogen receptor, tumor grade and lymph node status, the key factors of breast cancer aggressiveness, using untargeted proteomics. Here we verified these findings in the same set of 96 tumors using targeted proteomics based on selected reaction monitoring with mTRAQ labeling (mTRAQ-SRM), transcriptomics and immunohistochemistry and validated in 5 independent sets of 715 patients using transcriptomics. We confirmed: (i) positive association of anterior gradient protein 2 homolog (AGR2) and periostin (POSTN) and negative association of annexin Al (ANXA1) with estrogen receptor status; (ii) positive association of stathmin (STMN1), cofilin-1 (COF1), plasminogen activator inhibitor 1 RNA-binding protein (PAIRBPI) and negative associations of thrombospondin-2 (TSP2) and POSTN levels with tumor grade; and (iii) positive association of POSTN, alpha-actinin-4 (ACTN4) and STMN1 with lymph node status. This study highlights a panel of gene products that can contribute to breast cancer aggressiveness and metastasis, the understanding of which is important for development of more precise breast cancer treatment (C) 2017 Elsevier B.V. All rights reserved.

Links

GA14-19250S, research and development project

Name: Nový panel proteinů korelujících se stavem lymfatických uzlin u low-grade nádorů prsu: Klinická verifikace a úloha v invazivitě nádorových buněk

Investor: Czech Science Foundation

LM2015043, research and development project

Name: Česká infrastruktura pro integrativní strukturní biologii (Acronym: CIISB)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

PROCHÁZKOVÁ, Iva, Juraj LENČO, Alena FUČÍKOVÁ, Jiří DRESLER, Lenka ČÁPKOVÁ, Roman HRSTKA, Rudolf NENUTIL and Pavel BOUCHAL. Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness. Biochimica et Biophysica Acta - Proteins and Proteomics. AMSTERDAM: Elsevier Science, 2017, vol. 1865, No 5, p. 488-498. ISSN 1570-9639. Available from: https://dx.doi.org/10.1016/j.bbapap.2017.02.012.

@article{1412658,
   author = {Procházková, Iva and Lenčo, Juraj and Fučíková, Alena and Dresler, Jiří and Čápková, Lenka and Hrstka, Roman and Nenutil, Rudolf and Bouchal, Pavel},
   article_location = {AMSTERDAM},
   article_number = {5},
   doi = {http://dx.doi.org/10.1016/j.bbapap.2017.02.012},
   keywords = {Breast cancer; Selected reaction monitoring; mTRAQ; Estrogen receptor; Tumor grade; Lymph node},
   language = {eng},
   issn = {1570-9639},
   journal = {Biochimica et Biophysica Acta - Proteins and Proteomics},
   title = {Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness},
   volume = {1865},
   year = {2017}
}

TY  - JOUR
ID  - 1412658
AU  - Procházková, Iva - Lenčo, Juraj - Fučíková, Alena - Dresler, Jiří - Čápková, Lenka - Hrstka, Roman - Nenutil, Rudolf - Bouchal, Pavel
PY  - 2017
TI  - Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness
JF  - Biochimica et Biophysica Acta - Proteins and Proteomics
VL  - 1865
IS  - 5
SP  - 488-498
EP  - 488-498
PB  - Elsevier Science
SN  - 15709639
KW  - Breast cancer
KW  - Selected reaction monitoring
KW  - mTRAQ
KW  - Estrogen receptor
KW  - Tumor grade
KW  - Lymph node
N2  - Breast cancer is the most common and molecularly relatively well characterized malignant disease in women, however, its progression to metastatic cancer remains lethal for 78% of patients 5 years after diagnosis. Novel markers could identify the high risk patients and their verification using quantitative methods is essential to overcome genetic, inter-tumor and intra-tumor variability and translate novel findings into cancer diagnosis and treatment. We recently identified 13 proteins associated with estrogen receptor, tumor grade and lymph node status, the key factors of breast cancer aggressiveness, using untargeted proteomics. Here we verified these findings in the same set of 96 tumors using targeted proteomics based on selected reaction monitoring with mTRAQ labeling (mTRAQ-SRM), transcriptomics and immunohistochemistry and validated in 5 independent sets of 715 patients using transcriptomics. We confirmed: (i) positive association of anterior gradient protein 2 homolog (AGR2) and periostin (POSTN) and negative association of annexin Al (ANXA1) with estrogen receptor status; (ii) positive association of stathmin (STMN1), cofilin-1 (COF1), plasminogen activator inhibitor 1 RNA-binding protein (PAIRBPI) and negative associations of thrombospondin-2 (TSP2) and POSTN levels with tumor grade; and (iii) positive association of POSTN, alpha-actinin-4 (ACTN4) and STMN1 with lymph node status. This study highlights a panel of gene products that can contribute to breast cancer aggressiveness and metastasis, the understanding of which is important for development of more precise breast cancer treatment (C) 2017 Elsevier B.V. All rights reserved.
ER  -

PROCHÁZKOVÁ, Iva, Juraj LENČO, Alena FUČÍKOVÁ, Jiří DRESLER, Lenka ČÁPKOVÁ, Roman HRSTKA, Rudolf NENUTIL and Pavel BOUCHAL. Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness. \textit{Biochimica et Biophysica Acta - Proteins and Proteomics}. AMSTERDAM: Elsevier Science, 2017, vol.~1865, No~5, p.~488-498. ISSN~1570-9639. Available from: https://dx.doi.org/10.1016/j.bbapap.2017.02.012.

Detailed Information on Publication Record